The third-generation aromatase inhibitors (AIs), anastrozole, letrozole, and exemestane, are nowadays considered the standard adjuvant treatment for women with ER+ breast cancer because of their advantages over tamoxifen, and so studies have been conducted in order to confirm their superiority in the neoadjuvant setting. Here, ESR1 is linked to breast carcinoma.